BAFF/TNFSF13B, Cynomolgus, 重组蛋白 (hFc) TMPY-03645
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | 价格 | 操作 |
---|---|---|
500 μg | ¥10,170.00 | 询底价 |
200 μg | ¥5,020.00 | 询底价 |
100 μg | ¥2,930.00 | 询底价 |
Product Introduction
Bioactivity
英文名: BAFF/TNFSF13B Protein, Cynomolgus, Recombinant (hFc)
描述: B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is a single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors are a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS is an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
存储条件: Lyophilized powder: -20~-80°C for 1 year | Solution: -80°C for 6~12 month
BAFF/TNFSF13B, Cynomolgus, 重组蛋白 (hFc) TMPY-03645信息由TargetMol中国为您提供,如您想了解更多关于BAFF/TNFSF13B, Cynomolgus, 重组蛋白 (hFc) TMPY-03645报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途